Shares of Eris Lifesciences Ltd. have surged more than 80% since the pandemic lows. Yet, the surge masks modest returns since its listing five years ago. The company is immune to the twin banes Indian drugmakers have struggled to overcome in the U.S., their largest market: pricing pressure and regulatory scrutiny. Eris, a maker of formulations or finished drugs, is the only listed Indian pharma company that solely caters to the domes...